Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Steg, P. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Steg, P. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Overview of large morbidity/mortality trials with ivabradine: focus on the BEAUTIfUL study

Philippe Gabriel Steg

Centre Hospitalier Bichat-Claude Bernard, Université Denis Diderot, Paris VII, 46 rue Henri Huchard, 75877 Paris Cedex 18, France

Corresponding author. Tel: +33 1 40 25 86 68. E-mail address: gabriel.steg{at}bch.aphp.fr

Heart failure and left ventricular dysfunction complicating coronary artery disease (CAD) are associated with a poor prognosis. Beta-blockers have been shown to be beneficial for survival in these conditions, a benefit that is mediated, in part, through slowing of the heart rate. In addition, since heart rate is one of the major determinants of myocardial oxygen consumption, its lowering is associated with relief of ischaemia and anginal symptoms, and indeed, slowing the heart rate with beta-blockers is associated with effective relief of ischaemia. Therefore, in left ventricular dysfunction complicating CAD, there is potentially a major role for slowing the heart rate. Although effective, beta-blockers may not always achieve optimal heart rate lowering or may not be well tolerated. Ivabradine, a selective heart rate-lowering agent, is being tested compared with placebo, in addition to standard therapy (including beta-blockers, if tolerated) in the large morbidity/mortality BEAUTIfUL trial. This study was established to test the superiority of ivabradine compared with placebo as an adjunct to conventional therapy in the reduction of a composite endpoint of cardiovascular mortality, acute myocardial infarction (requiring hospital admission), and new or worsening heart failure (requiring hospital admission) in patients with stable CAD, in sinus rhythm, and with left ventricular dysfunction. Approximately 11 000 patients with evidence of CAD, a sinus rhythm of ≥60 bpm, and an ejection fraction of 39% or less were enrolled. In a randomized, double-blind fashion, patients are receiving ivabradine 5 mg twice daily titrated to 7.5 mg twice daily after 2 weeks, or matching placebo, in order to target a heart rate of <60 bpm. Holter electrocardiography, echocardiography, and NT-proBNP substudies are also planned.

The BEAUTIfUL trial will be an important step in determining the clinical importance of heart rate on the outcome of patients with CAD and left ventricular dysfunction.

Key Words: Coronary artery disease • Heart rate • Ivabradine • Left ventricular dysfunction • Randomized clinical trial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.